Evgen Pharma – a company focused on the development of sulforaphane-based medicines – has announced that it has completed the dosing of all three cohorts of its dose-escalating, placebo-controlled, randomised phase 1/1b clinical trial.
Evgen – a company developing sulforaphane-based treatments – has revealed that it has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating phase 1/1b clinical trial of SFX-01. The therapy is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen – a clinical stage company developing sulforaphane-based medicines for the treatment of cancer and other indications – has received regulatory approvals for a healthy volunteer study to examine the performance of SFX-01. The lead asset therapy is the company’s new enteric coated tablet formulation.
Evgen Pharma has entered a partnership with the University of Michigan in the US to analyse the potential anti-tumour effects of the company’s lead asset, SFX-01, for colorectal cancer.
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in preclinical models of glioblastoma (GBM) generated by Dr Claudio Festuccia and colleagues at the Universities of Aquila, Rome and Rieti, Italy (Colapietro et al, Pharmaceuticals, 2021, 14, 1082).
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in glioblastoma cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley of the University of Auckland, New Zealand in the pre-print journal BioRxIV (Leung, Wright and Baguley, 2021 https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1).
Evgen Pharma PLC (AIM:EVG, FRA:8EV) said its SFX-01 drug has been granted an orphan drug designation (OD) by the US Food and Drug Administration (FDA) for the treatment of malignant glioma.
Progress on metastatic breast cancer programme
UK-based Evgen Pharma has announced that it has now recruited a total of 102 patients into a trial investigating its lead asset SFX-01 in COVID-19.